Product Information
TRESIBA 100 UNIT/ML VIAL is a brand product labeled by Novo Nordisk, priced at $9.0243 per ML under NDC 00169266211. Its NADAC has been published 358 times since Aug 21, 2019.
Strength
100 U/mL
Manufacturer
Novo NordiskNDC
00169266211
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Last Updated
6/17/2026
Active Ingredients
INSULIN DEGLUDECApproval Type
Biologic (BLA)
FDA Application
BLA203314On Market Since
11/21/2018
Pharmacological Classes
Price Statistics
The NADAC for TRESIBA 100 UNIT/ML VIAL has been published 358 times since Aug 21, 2019, and over the history we have for it it has declined 72.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.0243 per ML |
|---|---|
| All-time high | $32.6531 (Aug 16, 2023) |
| All-time low | $9.0243 (May 20, 2026) |
| 52-week high | $32.5042 |
| 52-week low | $9.0243 |
| Median price | $32.5209 |
| Average price | $30.9486 |
| Largest weekly change | -72.2% (Jan 14, 2026) |
| Weeks tracked | 358 |
| Tracking since | Aug 21, 2019 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRESIBA 100 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for TRESIBA 100 UNIT/ML VIAL, manufactured by Novo Nordisk, is $9.0243 per ML (NDC 00169266211), effective Jun 24, 2026.
How has the price of TRESIBA 100 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for TRESIBA 100 UNIT/ML VIAL has declined 72.3%. It has been tracked across 358 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for TRESIBA 100 UNIT/ML VIAL?
Since Aug 21, 2019, the NADAC for TRESIBA 100 UNIT/ML VIAL has ranged from a low of $9.0243 (May 20, 2026) to a high of $32.6531 (Aug 16, 2023), with a median of $32.5209 per ML.
Are there cheaper alternatives to TRESIBA 100 UNIT/ML VIAL?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as TRESIBA 100 UNIT/ML VIAL, but none are currently priced below it.
Who manufactures TRESIBA 100 UNIT/ML VIAL?
TRESIBA 100 UNIT/ML VIAL (NDC 00169266211) is labeled by Novo Nordisk, and CMS classifies it as a brand product.
Related Drugs
Same classification